Re-listened to their 3rd quarter CC on Tribute's website. They expected the drugs in the Novartis deal to be immediately accretive, but were not going to be doing promotion via their sales reps until Q1 2015 on these drugs as I guess they are all getting up to speed. I suspect we will see a bigger bump in Q1 from the Novartis deal. They certainly look like they are on track to see a top line growth of 50% in 2015.
News 
Market Data 
Discover 
